Can a kidney drug stop acute injury from becoming chronic?

NCT ID NCT07775482

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether finerenone, a drug already used for chronic kidney disease, is safe and tolerable for people hospitalized with acute kidney injury (AKI). About 72 adults with moderate-to-severe AKI will receive either finerenone or a placebo once daily for up to 45 days, alongside standard care. The study aims to see if the drug can help prevent AKI from progressing to chronic kidney disease, while monitoring for side effects like high potassium and blood pressure changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
finerenone (Kerendia), an oral capsule taken once daily for up to 45 days
What this could lead to
If this works, finerenone could become a way to help people recover from acute kidney injury and reduce their risk of developing chronic kidney disease later.
What could go wrong
This is a small pilot study focused on feasibility, not proof of benefit. The drug may not improve outcomes, and it carries risks like high potassium levels and low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 0C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.